Spectrum of Findings Seen in Patients With

BACKGROUND

Cholangiocarcinoma-with a growing incidence rate and poor prognosis-is not an aggressive tumor that is not uncommon. Molecular profiling can reveal actionable aberrations in at least a third of the tumors. This is especially so in the case of intrahepatic cholangiocarcinoma (ICC), where mutations in the isocitrate dehydrogenase 1 and 2 genes (

METHODS AND RESULTS

We descriptively characterize the clinical, radiological, and histopathological findings of 12 such patients.

CONCLUSION

Our findings indicate an increasing need to personalize an approach for these patients with specific molecular alterations. With the advent of the

Déclaration de conflit d'intérêts

Declaration of Conflicts of InterestThe authors declare the following financial interests/personal relationships which may be considered as potential competing interests: PMK reports grants paid to the institution by Merck, Agenus Bio, Novartis, Advanced Accelerator Applications, Tersera, and Boston Scientific; a consultancy and advisory board relationship with Elicio (scientific advisory board member/shares/stock ownership); cofounder of Precision BioSensors Inc.; consultancy/advisory board fees from Guardant Health, Natera, Foundation Medicine, Illumina, BostonGene, Merck/MSD Oncology, Tempus, Bayer, Lilly, Delcath Systems, IPBA, QED Therapeutics, Boston Healthcare Associates, Servier, Taiho Oncology, Exact Sciences, Daiichi Sankyo/AstraZeneca, Eisai, Saga Diagnostics, Neogenomics, Do More Diagnostics AS, and Seattle Genetics; consulting fees paid to the institution by Taiho Pharmaceutical and Ipsen; receiving travel support from AstraZeneca for presentation of an investigator-initiated trial. All other authors have no conflicts of interest to report.